Ones To Watch News
Refine search
Pharmaceutical
US investment firm Blackstone has closed its sixth life sciences fund at $6.3 billion, marking the largest private vehicle ever raised for the sector. The oversubscribed fund is nearly 40% larger than its predecessor, underlining strong investor appetite for late-stage drug development financing. 31 March 2026
Biotechnology
New findings have been presented on a couple of late-stage candidates in hidradenitis suppurativa (HS) at the 2026 American Academy of Dermatology (AAD) Annual Meeting. 30 March 2026
Biotechnology
Swiss biotech Idorsia’s share rose 5.7% to 3.24 francs in early trading, after it announced positive top-line results from its Phase II dose-finding study evaluating 10mg, 25mg and 50mg doses of daridorexant – the company’s dual orexin receptor antagonist (DORA) – in pediatric patients aged 10 to < 18 years with insomnia disorder. 30 March 2026
Biotechnology
San Diego, USA-based late-stage biotech ADARx Pharmaceuticals announced the appointment of Ryan Fisk as chief financial officer and chief business officer. In this role, he will be responsible for leading finance, strategy, corporate development and investor relations for the company. 28 March 2026
Biotechnology
The company formerly known as Vaxess Technologies has announced a rebrand and is now calling itself Terrestrial Bio. 27 March 2026
Biotechnology
Averna Therapeutics, a US biotech developing novel genomic medicines based on gene insertion technology, has announced the appointments of Robert Mabry as chief scientific officer (CSO) and Richard Morris as chief financial officer (CFO). 27 March 2026
Biotechnology
Swiss pharma giant Novartis today announced that it has entered into an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. 27 March 2026
Biotechnology
Braveheart Bio, a US biotech developing therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced the appointment of Emil deGoma as chief medical officer (CMO). 26 March 2026
Biotechnology
US biotech Pinnacle Medicines, which is pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, today announced the closing of an oversubscribed $89 million Series B financing. 26 March 2026
Biotechnology
Retina-focused biotech Kodiak Sciences has announced positive topline results in the GLOW2 Phase III superiority study of Zenkuda (tarcocimab tedromer) for the treatment of patients with diabetic retinopathy. 26 March 2026
Pharmaceutical
More than two months before the US Food and Drug Administration (FDA) deadline date for a decision, the agency has approved Corcept Therapeutics’ Lifyorli (relacorilant) in ovarian cancer, sending shares in the firm 18% higher Wednesday. 26 March 2026
Biotechnology
US rare disease drug developer Sarepta Therapeutics allowed investors to forget the damaging saga of Elevidys (delandistrogene moxeparvovec), its gene therapy for Duchenne muscular dystrophy, by presenting some positive pipeline news Wednesday. 26 March 2026
Pharmaceutical
US pharma giant Merck & Co and Terns Pharmaceuticals, a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck will acquire Terns. 25 March 2026
Pharmaceutical
US clinical-stage firm Apnimed, which is developing an oral drug product candidate, AD109, that is designed to address a root cause of obstructive sleep apnea (OSA), has announced that Japan’s Shionogi have entered into a definitive agreement for Shionogi to acquire Apnimed's 50% ownership of Shionogi-Apnimed Sleep Science (SASS). 25 March 2026
Pharmaceutical
San Diego, USA-based Yatiri Bio, an AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor, for the treatment of acute myeloid leukemia (AML). 25 March 2026
Pharmaceutical
Karyopharm Therapeutics today reported top-line results from its Phase III SENTRY Trial in myelofibrosis that met the first co-primary endpoint, demonstrating statistically-significant improvement in spleen reduction volume. 24 March 2026
Biotechnology
UK-based Immutrin, a biotech developing next generation antibody therapy to reverse amyloidosis, has successfully raised £65 million ($87 million) in a Series A financing. 24 March 2026
Biotechnology
US biotech Ocugen today released full Phase II ArMaDa data for OCU410, its investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration. 24 March 2026
Biotechnology
Damora Therapeutics, a US biotech with the stated ambition of fundamentally redefining care for patients with blood disorders, has appointed Jennifer Jarrett as president and chief executive. 24 March 2026
Biotechnology
Gilead Sciences late yesterday revealed it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager (TCE) therapies for autoimmune diseases. 24 March 2026
Biotechnology
Belgium’s largest pharma company UCB announced that it has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. 18 April 2026
Biotechnology
For most of oncology’s history, the fight against cancer has begun once the disease is diagnosed. UK-based Athernal Bio is building its platform around an earlier and potentially more powerful point of intervention: addressing biological changes in the body that accumulate silently before cancer develops. 17 April 2026
Pharmaceutical
Recently-launched US obesity company Kailera Therapeutics has announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. 17 April 2026
Pharmaceutical
Achieve Life Sciences, a late-stage specialty pharma company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, has appointed Andrew Goldberg as its new chief executive and member of the board. 17 April 2026
Pharmaceutical
California-based liver and viral disease specialist Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection, the company announced yesterday. 17 April 2026
Biotechnology
Genetic medicines company MeiraGTx Holdings has reacquired global rights to its Phase III gene therapy candidate for X-linked retinitis pigmentosa (XLRP), botaretigene sparoparvovec (bota-vec), from Johnson & Johnson, and priced a $100 million public offering of ordinary shares to support advancement of its late-stage pipeline. 16 April 2026
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
German drug discovery company Evotec today announced the appointment of Dr Ingrid Müller as chief operating officer (COO). 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Pharmaceutical
US biopharma Travere Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze